September 13, 2017 / 2:31 PM / a year ago

Novo Nordisk's Xultophy reduces cardiovascular risks in people with type 2 diabetes

COPENHAGEN, Sept 13 (Reuters) - Novo Nordisk said at the Annual Meeting of the European Association For The Study Of Diabetes:

* Novo’s Xultophy drug “significantly reduced” a number of risk factors associated with an increased risk of cardiovascular disease, compared to basal insulin glargine U100 of Sanofi or its own insulin degludec, better known as Tresiba

* People treated with Xultophy had significantly lower systolic blood pressure, lower total cholesterol as well as lower low-density lipoprotein cholesterol (bad cholesterol)

* Cardiovascular diseases is the principal cause of death and disability among people with type 2 diabetes globally, with approximately two-thirds of deaths in people with diabetes attributable to CVD, according to Novo

* Xultophy is a once-daily single injection fixed-ratio combination of long-acting insulin degludec and the GLP-1 receptor agonist liraglutide (Victoza) in one pen (Reporting by Julie Astrid Thomsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below